Vitrolife AB (CHIX:VITRS) Other Current Liabilities: kr345 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:VITRS Vitrolife AB CHIX:VITRS
77 GF Score
Price kr105.75
GF Value kr178.62
! 6 Warning Signs
View Full Analysis

What is Vitrolife AB Other Current Liabilities?

Vitrolife AB CHIX:VITRS 77 Other Current Liabilities is kr345 Mil as of Jun. 2026. GuruFocus rates CHIX:VITRS with a GF Score™ of 77/100 and a GF Value™ of kr178.62. The stock has 6 warning signs investors should review.

Vitrolife AB's other current liabilities for the quarter that ended in Jun. 2026 was kr345 Mil.

Vitrolife AB's quarterly other current liabilities increased from Dec. 2025 (kr324 Mil) to Mar. 2026 (kr355 Mil) but then declined from Mar. 2026 (kr355 Mil) to Jun. 2026 (kr345 Mil).

Vitrolife AB's annual other current liabilities increased from Dec. 2023 (kr202 Mil) to Dec. 2024 (kr291 Mil) and increased from Dec. 2024 (kr291 Mil) to Dec. 2025 (kr324 Mil).

Vitrolife AB Other Current Liabilities Related Terms

Vitrolife AB Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Vitrolife AB's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vitrolife AB Other Current Liabilities Chart

Vitrolife AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 298.00 231.00 202.00 291.00 324.00

Vitrolife AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 286.00 288.00 324.00 355.00 345.00
CHIX:VITRS
77GF Score
Vitrolife AB CHIX:VITRS
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vitrolife AB Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of kr345 Mil mean?
Vitrolife AB (CHIX:VITRS) has a Other Current Liabilities of kr345 Mil as of Jun. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Vitrolife AB.
Is Vitrolife AB's Other Current Liabilities too high?
Vitrolife AB's current Other Current Liabilities is kr345 Mil. Overall, Vitrolife AB has a GF Score™ of 77/100, reflecting its overall financial health beyond just this single metric.
How does Vitrolife AB's Other Current Liabilities compare to ABT and SYK?
Vitrolife AB's Other Current Liabilities of kr345 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Medical Devices & Instruments company?
A good Other Current Liabilities depends on the Medical Devices & Instruments industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Vitrolife AB. Vitrolife AB's current Other Current Liabilities is kr345 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vitrolife AB stock overvalued right now?
Vitrolife AB (CHIX:VITRS) has a current Other Current Liabilities of kr345 Mil. The stock's GF Value™ is kr178.62, compared to a current price of kr105.75 — trading 40.8% below its estimated fair value. The current Other Current Liabilities is kr345 Mil. Vitrolife AB's overall GF Score™ is 77/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Vitrolife AB (CHIX:VITRS), the current Other Current Liabilities is kr345 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vitrolife AB (CHIX:VITRS) Overvalued in 2026?

Based on GuruFocus' analysis, Vitrolife AB stock appears to be undervalued. The current stock price of kr105.75 is trading 40.8% below its estimated GF Value™ of kr178.62.

Key valuation signals for CHIX:VITRS:

  • Other Current Liabilities: kr345 Mil
  • GF Value™: kr178.62 vs. price of kr105.75 (40.8% below fair value)
  • GF Score™: 77/100 with 6 warning signs

No single metric tells the full story. See the CHIX:VITRS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vitrolife AB Business Description

Address Box 9080, Gothenburg, SWE, 400 92
Vitrolife AB provides medical devices and genetic testing services intended for the reproductive-health market in the field of reproductive health. The company develops, manufactures, and distributes medical devices and provides genetic testing services for IVF clinics and their patients. Its mission is to support IVF clinics (in vitro fertilization) in enhancing their practice as well as the outcome of a patient's fertility treatment, thereby enabling patients to receive support to navigate the complexities of reproductive health through successful outcomes and patient satisfaction. The company has three geographical segments EMEA, Americas and APAC, out of which it derives maximum revenue from EMEA.
77GF Score

Get the complete analysis for CHIX:VITRS

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr105.75
Price
kr178.62
GF Value